Latest Earnings Results: Q3 '26
Estimated EPS
-$0.36
Reported EPS
-$0.42
Surprise
-15.55%
Estimated Rev
$14.27M
Reported Rev
$12.87M
Surprise
-9.8%
• Reported GAAP EPS of -$0.42 down -10.53% YoY • Reported revenue of $12.87M down -11.49% YoY • Ocular Therapeutix believes its $530.6M cash balance is sufficient to support planned operating expenses, debt service and capital expenditures into 2028; projection excludes full manufacturing and commercial-team scaling expenses.
Generated by Stocktwits using AI and company-reported earnings data for Q3 '26. This recap is intended to help readers understand the quarter quickly. Verify key figures in the linked source materials; the summary may contain errors and is not investment advice.
Historical Earnings
Quarterly
Annual
EPS
Revenue
| Fiscal Period | Estimated | Reported | Surprise | Result |
|---|---|---|---|---|
Q4 '26 | -$0.43 | -- | -- | N/A |
Q3 '26 | -$0.36 | -$0.42 | -15.55% | MISSED |
Q2 '26 | -$0.40 | -$0.35 | 11.49% | BEAT |
Q1 '26 | -$0.31 | -$0.40 | -27.07% | MISSED |
Q4 '25 | -$0.32 | -$0.29 | 9.62% | BEAT |